Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Valsartan 320 mg in Healthy Subjects Under Fasting Conditions
NCT02197442Phase 1Completed
- Sponsor
- Ranbaxy Laboratories
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of valsartan in hypertension (HTN) (2 arms), sponsored by Ranbaxy Laboratories. Primary endpoints: Area under the plasma concentration versus time curve and Peak Plasma Concentration. Started Jan 2014; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02197442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197442.